In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient’s T cells are engineered to better recognize and attack antigens on the surface of cancer cells.
Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review – Pharmaceutical Technology
The company also plans to initiate a Phase III trial for odronextamab, which evaluates the drug in earlier lines of therapy. Image Credit: Nemes Laszlo
September 29, 2023